CLAIM #3115 · Abbott Laboratories (ABT) · 2023Q4 earnings call · Jan 23, 2024 · due Dec 31, 2025
“Given the strength of the portfolio of team and what we went through and the actions that we've taken, I'd actually expect us to actually surpass our pre-recall share. I don't know exactly when, but that will be my expectation on that.”
Robert Ford · CEO
PENDING
graded after results covering Dec 31, 2025 are reported
Verify independently
SEC filings for ABT ↗ · Claim quote is verbatim from the 2023Q4 earnings call.